Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, ...

Marlborough: Boston Scientific Corporation has announced that the company has received approval from the U.S. Food and Drug ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Boston Scientific (NYSE:BSX) recently achieved FDA approval to expand the FARAPULSE™ Pulsed Field Ablation (PFA) System's use, enhancing treatment options for persistent atrial fibrillation. This ...

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval to expand the ...

Boston Scientific (NYSE: BSX) announced that the FDA approved an expansion to the label of its Farapulse pulsed field ...

Boston Scientific Corp. gained a second U.S. FDA approval for its Farapulse pulsed field ablation catheter, expanding its use into drug-refractory, symptomatic persistent atrial fibrillation (AF) in ...

For patients with atrial fibrillation, catheter ablation reduces the risks for ischemic stroke at more than 30 days, ...

Memorial Health System’s Department of Cardiology has announced the successful launch of the FARAPULSE Pulsed Field Ablation ...

On the heels of the first pulsed-field ablation device to win approval for atrial fibrillation ablation, a novel version of ...

Trial achieves positive results in the treatment of persistent atrial fibrillation Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy ...